Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Leo Reap

Internal Medicine Bingham Farms, MI Doctor of Osteopathy

NPI 1568844082 CMS profile 1368092

31500 Telegraph Rd Ste 225, Bingham Farms, MI 48025

Open in the dashboard

General payments

$4,326

123 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$203,903 paid to institutions, not to them · program years 2024–2025

Through program year 2025, Leo Reap of Bingham Farms, MI is reported in the CMS Open Payments database as having received $4,326 across 123 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $203,903 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 88th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,575 45
2024 General $345 13
2023 General $674 15
2022 General $169 5
2021 General $209 2
2020 General $573 6
2019 General $782 37

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Leo Reap
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Leo Reap were reported at $1,575. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Leo Reap Internal Medicine median Middle half National median
2019 $782 $159 $48–$570 $163
2020 $573 $119 $33–$402 $114
2021 $209 $135 $37–$521 $132
2022 $169 $141 $42–$496 $149
2023 $674 $149 $45–$519 $160
2024 $345 $154 $47–$537 $164
2025 $1,575 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $1,347 24 payments
  2. Gilead Sciences, Inc. $686 21 payments
  3. Genentech USA, Inc. $370 6 payments
  4. Kite Pharma, Inc. $285 6 payments
  5. Janssen Biotech, Inc. $272 4 payments
  6. E.R. Squibb & Sons, L.L.C. $259 16 payments
  7. AbbVie, Inc. $192 7 payments
  8. Incyte Corporation $125 1 payment
  9. Astellas Pharma US Inc $114 2 payments
  10. Eisai Inc. $63 3 payments
  11. Other $614 33 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,980 108 payments
  2. Long term medical supply or device loan $698 7 payments
  3. Education $648 8 payments
Products named General payments · program years 2019–2025
  1. KISQALI $839 15 payments
  2. Trodelvy $510 16 payments
  3. Alecensa $245 3 payments
  4. TECENTRIQ $245 3 payments
  5. KYMRIAH $240 2 payments
  6. OPDIVO $181 9 payments
  7. RYBREVANT $149 3 payments
  8. EPKINLY $131 4 payments
  9. MONJUVI $125 1 payment
  10. IMBRUVICA $123 1 payment
  11. Other $1,445 63 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 36 drugs

Part D claims

1,200

Median for Internal Medicine: 777

Drug cost

$3,880,762

Median for Internal Medicine: $73,373

Branded share of claims

40.2%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Brukinsa Zanubrutinib Brand 62 $880,310
Lenalidomide Generic 58 $799,597
Revlimid Lenalidomide Brand 23 $501,169
Ibrance Palbociclib Brand 21 $327,479
Imbruvica Ibrutinib Brand 23 $271,895
Sprycel Dasatinib Brand 19 $263,369
Pomalyst Pomalidomide Brand 12 $244,831
Nubeqa Darolutamide Brand 14 $181,974
Ninlaro Ixazomib Citrate Brand 11 $144,931
Tasigna Nilotinib Hcl Brand 12 $116,892

The 10 drugs with the highest cost, of 36 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 15 billing codes

Paid by Medicare

$73,805

Medicare's payments for the services billed

Medicare patients

366

Average age 74

Services billed

897

213 women, 153 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Cancer 42%
Chronic kidney disease 40%
Diabetes 39%
Ischemic heart disease 34%
COPD 30%
Heart failure 29%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RYBREVANT
  • Janssen Biotech, Inc. $149
$149 — —
EPKINLY
  • Genmab U.S., Inc. $28
$28 — —
XTANDI
  • Astellas Pharma US Inc $19
$19 — —
OPDUALAG
  • E.R. Squibb & Sons, L.L.C. $18
$18 — —
Yescarta
  • Kite Pharma, Inc. $18
$18 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

123 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record